The new five-year project, which aims to optimize binding kinetics for drug candidates to improve drug design, will receive €20m in funding from Europe’s Innovative Medicines Initiative, a public-private partnership.
K4DD consortium coordinator Anke Müller-Fahrnow said K4DD sets an example of public-private partnership to tackle specific drug discovery problems of today and to come up with new concepts in modern drug discovery.
”We have assembled a large experienced team of kinetics experts from academic institutions and industrial partners to create a Europe-wide network of complementary capabilities extending far beyond the scope of a traditional ‘one-on-one’ industry-academia collaboration," Müller-Fahrnow added.
Leiden University Center for Drug Research medicinal chemistry professor Ad P. Ijzerman said, "We welcome the unique opportunity afforded by this IMI initiative."
The K4DD consortium with 20 partners, consists of pharma companies, universities, knowledge institutes and smaller companies throughout Europe.